Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature

Authors Sgherza N, Abruzzese E, Perla G, Minervini MM, Chiello V, Sciannamè N, Cascavilla N

Received 15 March 2017

Accepted for publication 25 April 2017

Published 27 June 2017 Volume 2017:13 Pages 751—755


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Nicola Sgherza,1 Elisabetta Abruzzese,2 Gianni Perla,1 Maria Marta Minervini,1 Vincenzo Chiello,1 Natale Sciannamè,3 Nicola Cascavilla1

1Hematology, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo (FG), 2Hematology, Sant’Eugenio Hospital, Roma, 3Gynecology and Obstetrics, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo (FG), Italy

Abstract: Approximately 10%–12% of patients in chronic-phase chronic myeloid leukemia (CP-CML) have additional chromosomal aberrations at diagnosis; moreover, CML occurs in up to 10% of pregnancy-associated leukemias, with an annual incidence of 1 per 100,000 pregnancies. In this report we describe the case of a 36-year-old female with CP-CML diagnosed in the 18th week of pregnancy and with a new complex variant translocation t(4;9;22;21)(q24;q34;q11;q22) and an additional chromosomal aberration t(1;20)(p36;p11). In consideration of her pregnancy, the patient strictly monitored her blood cell count without any specific treatment. At 32 weeks of pregnancy, the patient delivered via cesarean section a healthy baby girl. After 10 days from childbirth, dasatinib was started at a standard dosage of 100 mg/day and 3 months later complete cytogenetic response and major molecular response were obtained, with the achievement of an optimal response according to European Leukemia Net recommendations and showing efficacy of this tyrosine kinase inhibitor (TKI) in the presence of a complex karyotype.

Keywords: chronic myeloid leukemia, complex karyotype, pregnancy, additional chromosomal aberration, variant translocation, tyrosine kinase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]